Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ...

The combination of sintilimab and fruquintinib received conditional approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer ...

Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC ...

Chinese pair Hutchmed and Innovent Biologics have announced that the FRUSICA-2 Phase II/III trial of fruquintinib and ...

in patients with metastatic clear cell renal cell carcinoma (RCC), investigators report. PSMA is a known biomarker in prostate cancer, but it is also a marker of tumor angiogenesis in several ...

which evaluated sintilimab in combination with fruquintinib as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China, has met its primary endpoint of ...

which is overexpressed in > 85% of renal cell carcinomas (RCCs). We evaluated the safety and efficacy of motexafin gadolinium (MGd), a Trx inhibitor, as a single-agent therapy for metastatic RCC.

previous contralateral nephrectomy or irreversible impairment of contralateral renal function from a benign disorder, have absolute indications for NSS. Patients with bilateral RCC also have an ...

(Alliance News) - Hutchmed China Ltd on Wednesday hailed results of a clinical trial evaluating its kidney cancer treatment in China, while it reported an annual revenue dive. The Hong Kong-based ...

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...